PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate
the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the
de-intensification radical chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab
plus induction chemotherapy followed by radiotherapy alone) in high-risk locoregionally
advanced nasopharyngeal carcinoma.